Medannex is an award-winning Scottish biopharmaceutical company committed to unlocking the therapeutic potential of targeting annexin-A1, to create a first-in-class therapy to improve the lives of people impacted by cancers and autoimmune diseases. A first-in-human clinical trial of the company’s lead molecule – a monoclonal antibody known as ‘MDX-124’ - has been initiated. In non-clinical testing MDX-124 has demonstrated multifaceted anti-cancer activity.